SCHEMBL22221672

SCHEMBL22221672

CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)Nc1cnc(Cl)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 4/20 0.62
▸ CYP3A4 P08684 4/20 0.62
▸ CYP2C19 P33261 4/20 0.62
▸ CYP2C9 P11712 3/20 0.62
▸ CYP2D6 P10635 2/20 0.62
▸ ALDH1A1 P00352 3/20 0.58
▸ PPARA Q07869 6/20 0.58
▸ PPARG P37231 2/20 0.58
▸ FABP2 P12104 1/20 0.58
▸ SLC22A12 Q96S37 1/20 0.58
▸ MAPT P10636 5/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ USP2 O75604 3/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ HPGD P15428 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ ADORA3 P0DMS8 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22221513 0.88 CYP1A2 (0.61) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221573 0.87 CYP1A2 (0.58) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221517 0.86 CYP1A2 (0.58) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221581 0.84 CYP1A2 (0.88) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221475 0.84 PPARA (0.67) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221512 0.83 CYP1A2 (0.64) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221509 0.83 CYP1A2 (0.62) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221438 0.82 CYP1A2 (0.64) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221563 0.82 CYP1A2 (0.89) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL22221537 0.80 PPARA (0.68) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE UNIV LOUISIANA STATE (US) 2022-09-29 — — US disclosed
WO-2020146876-A2 ANTI-CANCER COMPOSITIONS AND METHODS OF USE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2020-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 CYP1A2 3362/4885CYP3A4 3638/4885CYP2C19 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback